This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and efficacy of N-001 in animal models. N-001 selectively targets sensory neurons and acts intracellularly to induce reversible depolymerization of the actin cytoskeleton, reducing pain signaling without interacting with the central nervous system. This innovative approach aims to provide effective acute pain management without the risk of substance use disorders associated with current pain medications. Successful completion of this project will support an Investigational New Drug (IND) filing to enable future clinical trials of N-001 as a pain therapeutic.
Generated 7/16/24, 5:23 AM